Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study.
暂无分享,去创建一个
M. Fujita | R. Nagai | K. Shimada | M. Yoshiyama | T. Kohro | Doubun Hayashi | T. Yamazaki | J. Yoshikawa | S. Fukuda
[1] J. Obata,et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. , 2012, Journal of cardiology.
[2] T. Murohara,et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. , 2012, Journal of cardiology.
[3] H. Daida,et al. Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[4] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.
[5] T. Sakamoto,et al. "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[6] F. Sellke,et al. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. , 2010, Atherosclerosis.
[7] V. Manolopoulos,et al. Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia , 2010, Heart and Vessels.
[8] N. Kaneko,et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[9] M. Fujita,et al. Elevated serum C-reactive protein levels predict cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[10] Adrian Hernandez,et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. , 2009, American heart journal.
[11] G. Ginsburg,et al. Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response , 2008, Circulation. Cardiovascular genetics.
[12] R. Nagai,et al. Demographics and changes in medical/interventional treatment of coronary artery disease patients over a 3.5-year period in Japan: the Japanese Coronary Artery Disease Study: trend examination. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[13] D. Rader,et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. , 2008, Journal of the American College of Cardiology.
[14] Deborah A Nickerson,et al. Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment , 2008, Circulation.
[15] R. Nagai,et al. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[16] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.
[17] T. Strandberg,et al. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. , 2006, Journal of the American College of Cardiology.
[18] Leiv Ose,et al. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[19] Raimund Erbel,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.
[20] Feng Lin,et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. , 2006, The American journal of cardiology.
[21] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[22] K. Shimada,et al. Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.
[23] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[24] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[25] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[26] H. Gylling,et al. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. , 2003, The Journal of laboratory and clinical medicine.
[27] H. Ueshima,et al. What cause of mortality can we predict by cholesterol screening in the Japanese general population? , 2003, Journal of internal medicine.
[28] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[29] Y. Matsuzawa,et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[30] Y. Matsuzawa,et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[31] Toru Suzuki,et al. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. , 2002, Clinical biochemistry.
[32] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[33] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[34] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[35] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[36] D Kromhout,et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.
[37] C. Shear,et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Effect of Patient Characteristics on Lovastatin‐Induced Changes in Plasma Concentrations of Lipids and Lipoproteins , 1992, Circulation.
[38] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.